ISG15 and immune diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 5, 2010, Pages 485-496

  Jeon, Young Joo ^a   Yoo, Hee Min ^a   Chung, Chin Ha ^a  

^a Seoul National University   (South Korea)

Author keywords

Immune diseases; ISG15; Type I interferons; UbcH8; UBE1L; UBP43; Viral infection

Indexed keywords

INTERFERON STIMULATED GENE 15 PROTEIN; LIGASE; PROTEIN UBP43; PROTEINASE; TRANSCRIPTION FACTOR; UBIQUITIN ACTIVATING E1 LIGASE; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CARCINOGENESIS; ENZYME ACTIVITY; IMMUNOPATHOLOGY; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRUS ACTIVATION; VIRUS INFECTION;

CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES; UBIQUITINS;

MAMMALIA;

EID: 77950368491     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.02.006     Document Type: Review

References (180)

1. Friedman R.M. Clinical uses of interferons. Br. J. Clin. Pharmacol. 2008, 65:158-162.
2. Isaacs A., Lindenmann J. Virus interference: I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:258-267.
3. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
4. Heim M.H., Kerr I.M., Stark G.R., Darnell J.E. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995, 267:1347-1349.
5. Shuai K., Stark G.R., Kerr I.M., Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
6. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 2000, 25:496-502.
7. Heim M.H. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J. Recept. Signal. Transduct. Res. 1999, 19:75-120.
8. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
9. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809. 778-809, table of contents.
10. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
11. Hochstrasser M. Evolution and function of ubiquitin-like protein-conjugation systems. Nat. Cell Biol. 2000, 2:E153-E157.
12. Kim K.I., Zhang D.E. ISG15, not just another ubiquitin-like protein. Biochem. Biophys. Res. Commun. 2003, 307:431-434.
13. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
14. Hicke L. Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell. Biol. 2001, 2:195-201.
15. Jentsch S., Pyrowolakis G. Ubiquitin and its kin: how close are the family ties?. Trends Cell Biol. 2000, 10:335-342.
16. Farrell P.J., Broeze R.J., Lengyel P. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature 1979, 279:523-525.
17. Haas A.L., Ahrens P., Bright P.M., Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J. Biol. Chem. 1987, 262:11315-11323.
18. Yuan W., Krug R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 2001, 20:362-371.
19. Nielsch U., Pine R., Zimmer S.G., Babiss L.E. Induced expression of the endogenous beta interferon gene in adenovirus type 5-transformed rat fibroblasts. J. Virol. 1992, 66:1884-1890.
20. Lai C., Struckhoff J.J., Schneider J., Martinez-Sobrido L., Wolff T., Garcia-Sastre A., Zhang D.E., Lenschow D.J. Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J. Virol. 2009, 83:1147-1151.
21. Hsiang T.Y., Zhao C., Krug R.M. Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. J. Virol. 2009, 83:5971-5977.
22. Lenschow D.J., Lai C., Frias-Staheli N., Giannakopoulos N.V., Lutz A., Wolff T., Osiak A., Levine B., Schmidt R.E., Garcia-Sastre A., Leib D.A., Pekosz A., Knobeloch K.P., Horak I., Virgin H.W.t. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1371-1376.
23. Kunzi M.S., Pitha P.M. Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. J. Interferon Cytokine Res. 1996, 16:919-927.
24. Okumura A., Lu G., Pitha-Rowe I., Pitha P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1440-1445.
25. Okumura A., Pitha P.M., Harty R.N. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3974-3979.
26. Malakhova O.A., Zhang D.E. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J. Biol. Chem. 2008, 283:8783-8787.
27. Frias-Staheli N., Giannakopoulos N.V., Kikkert M., Taylor S.L., Bridgen A., Paragas J., Richt J.A., Rowland R.R., Schmaljohn C.S., Lenschow D.J., Snijder E.J., Garcia-Sastre A., Virgin H.W.t. Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe 2007, 2:404-416.
28. Guerra S., Caceres A., Knobeloch K.P., Horak I., Esteban M. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 2008, 4:e1000096.
29. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 2001, 14:661-664.
30. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
31. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 2002, 29:18-26.
32. Andersen J.B., Hassel B.A. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe?. Cytokine Growth Factor Rev. 2006, 17:411-421.
33. Pitha-Rowe I., Hassel B.A., Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J. Biol. Chem. 2004, 279:18178-18187.
34. Kitareewan S., Pitha-Rowe I., Sekula D., Lowrey C.H., Nemeth M.J., Golub T.R., Freemantle S.J., Dmitrovsky E. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3806-3811.
35. Liu M., Hummer B.T., Li X., Hassel B.A. Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J. Interferon Cytokine Res. 2004, 24:647-654.
36. Ohwada S., Kobayashi I., Maemura M., Satoh Y., Ogawa T., Iino Y., Morishita Y. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett. 1996, 110:149-154.
37. Shah S.J., Blumen S., Pitha-Rowe I., Kitareewan S., Freemantle S.J., Feng Q., Dmitrovsky E. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol. Cancer Ther. 2008, 7:905-914.
38. Andersen J.B., Aaboe M., Borden E.C., Goloubeva O.G., Hassel B.A., Orntoft T.F. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br. J. Cancer 2006, 94:1465-1471.
39. Desai S.D., Haas A.L., Wood L.M., Tsai Y.C., Pestka S., Rubin E.H., Saleem A., Nur E.K.A., Liu L.F. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res. 2006, 66:921-928.
40. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., van Heek N.T., Rosty C., Walter K., Sato N., Parker A., Ashfaq R., Jaffee E., Ryu B., Jones J., Eshleman J.R., Yeo C.J., Cameron J.L., Kern S.E., Hruban R.H., Brown P.O., Goggins M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 2003, 162:1151-1162.
41. Narasimhan J., Wang M., Fu Z., Klein J.M., Haas A.L., Kim J.J. Crystal structure of the interferon-induced ubiquitin-like protein ISG15. J. Biol. Chem. 2005, 280:27356-27365.
42. Liu Y.C., Pan J., Zhang C., Fan W., Collinge M., Bender J.R., Weissman S.M. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4313-4318.
43. Raasi S., Schmidtke G., Groettrup M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 2001, 276:35334-35343.
44. Hipp M.S., Kalveram B., Raasi S., Groettrup M., Schmidtke G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol. Cell. Biol. 2005, 25:3483-3491.
45. Knight E., Fahey D., Cordova B., Hillman M., Kutny R., Reich N., Blomstrom D. A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor. J. Biol. Chem. 1988, 263:4520-4522.
46. Liu M., Reimschuessel R., Hassel B.A. Molecular cloning of the fish interferon stimulated gene, 15kDa (ISG15) orthologue: a ubiquitin-like gene induced by nephrotoxic damage. Gene 2002, 298:129-139.
47. Loeb K.R., Haas A.L. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 1992, 267:7806-7813.
48. Chang Y.G., Yan X.Z., Xie Y.Y., Gao X.C., Song A.X., Zhang D.E., Hu H.Y. Different roles for two ubiquitin-like domains of ISG15 in protein modification. J. Biol. Chem. 2008, 283:13370-13377.
49. Giannakopoulos N.V., Arutyunova E., Lai C., Lenschow D.J., Haas A.L., Virgin H.W. ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important for innate immune control of Sindbis virus. J. Virol. 2009, 83:1602-1610.
50. Reich N., Evans B., Levy D., Fahey D., Knight E., Darnell J.E. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:6394-6398.
51. Nakaya T., Sato M., Hata N., Asagiri M., Suemori H., Noguchi S., Tanaka N., Taniguchi T. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem. Biophys. Res. Commun. 2001, 283:1150-1156.
52. Au W.C., Moore P.A., Lowther W., Juang Y.T., Pitha P.M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11657-11661.
53. Daly C., Reich N.C. Characterization of specific DNA-binding factors activated by double-stranded RNA as positive regulators of interferon alpha/beta-stimulated genes. J. Biol. Chem. 1995, 270:23739-23746.
54. Weaver B.K., Kumar K.P., Reich N.C. Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol. Cell. Biol. 1998, 18:1359-1368.
55. Memet S., Besancon F., Bourgeade M.F., Thang M.N. Direct induction of interferon-gamma- and interferon-alpha/beta-inducible genes by double-stranded RNA. J. Interferon Res. 1991, 11:131-141.
56. Li J., Peet G.W., Balzarano D., Li X., Massa P., Barton R.W., Marcu K.B. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J. Biol. Chem. 2001, 276:18579-18590.
57. Gessani S., Belardelli F., Pecorelli A., Puddu P., Baglioni C. Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages. J. Virol. 1989, 63:2785-2789.
58. Malakhova O., Malakhov M., Hetherington C., Zhang D.E. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J. Biol. Chem. 2002, 277:14703-14711.
59. Hamerman J.A., Hayashi F., Schroeder L.A., Gygi S.P., Haas A.L., Hampson L., Coughlin P., Aebersold R., Aderem A. Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog. J. Immunol. 2002, 168:2415-2423.
60. Kim K.I., Malakhova O.A., Hoebe K., Yan M., Beutler B., Zhang D.E. Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J. Immunol. 2005, 175:847-854.
61. McKinnon P.J. Ataxia-telangiectasia: an inherited disorder of ionizing-radiation sensitivity in man. Progress in the elucidation of the underlying biochemical defect. Hum. Genet. 1987, 75:197-208.
62. Jung M., Zhang Y., Lee S., Dritschilo A. Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated I kappa B-alpha. Science 1995, 268:1619-1621.
63. Siddoo-Atwal C., Haas A.L., Rosin M.P. Elevation of interferon beta-inducible proteins in ataxia telangiectasia cells. Cancer Res. 1996, 56:443-447.
64. 2/M progression. Mol. Cell 1997, 1:3-11.
65. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305.
66. Hummer B.T., Li X.L., Hassel B.A. Role for p53 in gene induction by double-stranded RNA. J. Virol. 2001, 75:7774-7777.
67. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
68. Han S.Y., Kim S.H., Heasley L.E. Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts. J. Biol. Chem. 2002, 277:47167-47174.
69. Kaur S., Sassano A., Joseph A.M., Majchrzak-Kita B., Eklund E.A., Verma A., Brachmann S.M., Fish E.N., Platanias L.C. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J. Immunol. 2008, 181:7316-7323.
70. Yang L., Zhao H., Li S.W., Ahrens K., Collins C., Eckenrode S., Ruan Q.G., McIndoe R.A., She J.X. Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells. J. Mol. Diagn. 2003, 5:212-221.
71. Liu T.X., Zhang J.W., Tao J., Zhang R.B., Zhang Q.H., Zhao C.J., Tong J.H., Lanotte M., Waxman S., Chen S.J., Mao M., Hu G.X., Zhu L., Chen Z. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000, 96:1496-1504.
72. Gianni M., Terao M., Fortino I., LiCalzi M., Viggiano V., Barbui T., Rambaldi A., Garattini E. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997, 89:1001-1012.
73. Kok K., Hofstra R., Pilz A., van den Berg A., Terpstra P., Buys C.H., Carritt B. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6071-6075.
74. Durfee L.A., Kelley M.L., Huibregtse J.M. The basis for selective E1-E2 interactions in the ISG15 conjugation system. J. Biol. Chem. 2008, 283:23895-23902.
75. Kim K.I., Yan M., Malakhova O., Luo J.K., Shen M.F., Zou W., de la Torre J.C., Zhang D.E. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol. Cell. Biol. 2006, 26:472-479.
76. Kok K., Naylor S.L., Buys C.H. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv. Cancer Res. 1997, 71:27-92.
77. McLaughlin P.M., Helfrich W., Kok K., Mulder M., Hu S.W., Brinker M.G., Ruiters M.H., de Leij L.F., Buys C.H. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int. J. Cancer 2000, 85:871-876.
78. Yin X., Cong X., Yan M., Zhang D.E. Alteration of tumor spectrum by ISGylation in p53-deficient mice. Cancer Biol. Ther. 2009, 8:1167-1172.
79. Yin X., Cong X., Yan M., Zhang D.E. Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer 2009, 63:194-200.
80. Nyman T.A., Matikainen S., Sareneva T., Julkunen I., Kalkkinen N. Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur. J. Biochem. 2000, 267:4011-4019.
81. Kim K.I., Giannakopoulos N.V., Virgin H.W., Zhang D.E. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol. Cell. Biol. 2004, 24:9592-9600.
82. Zhao C., Beaudenon S.L., Kelley M.L., Waddell M.B., Yuan W., Schulman B.A., Huibregtse J.M., Krug R.M. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7578-7582.
83. Takeuchi T., Iwahara S., Saeki Y., Sasajima H., Yokosawa H. Link between the ubiquitin conjugation system and the ISG15 conjugation system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme. J. Biochem. 2005, 138:711-719.
84. Kumar S., Kao W.H., Howley P.M. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J. Biol. Chem. 1997, 272:13548-13554.
85. Chin L.S., Vavalle J.P., Li L. Staring, a novel E3 ubiquitin-protein ligase that targets syntaxin 1 for degradation. J. Biol. Chem. 2002, 277:35071-35079.
86. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 2000, 275:35661-35664.
87. Kramer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., Gottlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22:3411-3420.
88. Niwa J., Ishigaki S., Doyu M., Suzuki T., Tanaka K., Sobue G. A novel centrosomal ring-finger protein, dorfin, mediates ubiquitin ligase activity. Biochem. Biophys. Res. Commun. 2001, 281:706-713.
89. Urano T., Saito T., Tsukui T., Fujita M., Hosoi T., Muramatsu M., Ouchi Y., Inoue S. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002, 417:871-875.
90. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13354-13359.
91. Arimoto K., Konishi H., Shimotohno K. UbcH8 regulates ubiquitin and ISG15 conjugation to RIG-I. Mol. Immunol. 2008, 45:1078-1084.
92. Zou W., Zhang D.E. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J. Biol. Chem. 2006, 281:3989-3994.
93. Leaman D.W., Chawla-Sarkar M., Jacobs B., Vyas K., Sun Y., Ozdemir A., Yi T., Williams B.R., Borden E.C. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J. Interferon Cytokine Res. 2003, 23:745-756.
94. Nakasato N., Ikeda K., Urano T., Horie-Inoue K., Takeda S., Inoue S. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15. Biochem. Biophys. Res. Commun. 2006, 351:540-546.
95. Zou W., Wang J., Zhang D.E. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem. Biophys. Res. Commun. 2007, 354:321-327.
96. Okumura F., Zou W., Zhang D.E. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev. 2007, 21:255-260.
97. Takeuchi T., Inoue S., Yokosawa H. Identification and Herc5-mediated ISGylation of novel target proteins. Biochem. Biophys. Res. Commun. 2006, 348:473-477.
98. Wong J.J., Pung Y.F., Sze N.S., Chin K.C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10735-10740.
99. Dastur A., Beaudenon S., Kelley M., Krug R.M., Huibregtse J.M. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J. Biol. Chem. 2006, 281:4334-4338.
100. Malakhov M.P., Malakhova O.A., Kim K.I., Ritchie K.J., Zhang D.E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 2002, 277:9976-9981.
101. Ritchie K.J., Hahn C.S., Kim K.I., Yan M., Rosario D., Li L., de la Torre J.C., Zhang D.E. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat. Med. 2004, 10:1374-1378.
102. Catic A., Fiebiger E., Korbel G.A., Blom D., Galardy P.J., Ploegh H.L. Screen for ISG15-crossreactive deubiquitinases. PLoS One 2007, 2:e679.
103. Potter J.L., Narasimhan J., Mende-Mueller L., Haas A.L. Precursor processing of pro-ISG15/UCRP, an interferon-beta-induced ubiquitin-like protein. J. Biol. Chem. 1999, 274:25061-25068.
104. Li X.L., Blackford J.A., Judge C.S., Liu M., Xiao W., Kalvakolanu D.V., Hassel B.A. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J. Biol. Chem. 2000, 275:8880-8888.
105. Kang D., Jiang H., Wu Q., Pestka S., Fisher P.B. Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH. Gene 2001, 267:233-242.
106. Liu L.Q., Ilaria R., Kingsley P.D., Iwama A., van Etten R.A., Palis J., Zhang D.E. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol. Cell. Biol. 1999, 19:3029-3038.
107. Tokarz S., Berset C., La Rue J., Friedman K., Nakayama K., Zhang D.E., Lanker S. The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase. J. Biol. Chem. 2004, 279:46424-46430.
108. Schwer H., Liu L.Q., Zhou L., Little M.T., Pan Z., Hetherington C.J., Zhang D.E. Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43. Genomics 2000, 65:44-52.
109. Ritchie K.J., Malakhov M.P., Hetherington C.J., Zhou L., Little M.T., Malakhova O.A., Sipe J.C., Orkin S.H., Zhang D.E. Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev. 2002, 16:2207-2212.
110. Knobeloch K.P., Utermohlen O., Kisser A., Prinz M., Horak I. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol. Cell. Biol. 2005, 25:11030-11034.
111. Malakhova O.A., Yan M., Malakhov M.P., Yuan Y., Ritchie K.J., Kim K.I., Peterson L.F., Shuai K., Zhang D.E. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 2003, 17:455-460.
112. Malakhova O.A., Kim K.I., Luo J.K., Zou W., Kumar K.G., Fuchs S.Y., Shuai K., Zhang D.E. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006, 25:2358-2367.
113. Kim J.H., Luo J.K., Zhang D.E. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J. Immunol. 2008, 181:6467-6472.
114. Yan M., Luo J.K., Ritchie K.J., Sakai I., Takeuchi K., Ren R., Zhang D.E. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood 2007, 110:305-312.
115. Zhao C., Denison C., Huibregtse J.M., Gygi S., Krug R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10200-10205.
116. Malakhov M.P., Kim K.I., Malakhova O.A., Jacobs B.S., Borden E.C., Zhang D.E. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem. 2003, 278:16608-16613.
117. Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J., Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem. Biophys. Res. Commun. 2005, 336:496-506.
118. Knight E., Cordova B. IFN-induced 15-kDa protein is released from human lymphocytes and monocytes. J. Immunol. 1991, 146:2280-2284.
119. Recht M., Borden E.C., Knight E. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J. Immunol. 1991, 147:2617-2623.
120. D'Cunha J., Knight E., Haas A.L., Truitt R.L., Borden E.C. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:211-215.
121. Stossel T.P., Condeelis J., Cooley L., Hartwig J.H., Noegel A., Schleicher M., Shapiro S.S. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell. Biol. 2001, 2:138-145.
122. van der Flier A., Sonnenberg A. Structural and functional aspects of filamins. Biochim. Biophys. Acta 2001, 1538:99-117.
123. Jeon Y.J., Choi J.S., Lee J.Y., Yu K.R., Ka S.H., Cho Y., Choi E.J., Baek S.H., Seol J.H., Park D., Bang O.S., Chung C.H. Filamin B serves as a molecular scaffold for type I interferon-induced c-Jun NH2-terminal kinase signaling pathway. Mol. Biol. Cell 2008, 19:5116-5130.
124. Whitmarsh A.J. Filamin B: a scaffold for interferon signalling. EMBO Rep. 2009, 10:349-351.
125. Jeon Y.J., Choi J.S., Lee J.Y., Yu K.R., Kim S.M., Ka S.H., Oh K.H., Kim K.I., Zhang D.E., Bang O.S., Chung C.H. ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep. 2009, 10:374-380.
126. Hanada M., Ninomiya-Tsuji J., Komaki K., Ohnishi M., Katsura K., Kanamaru R., Matsumoto K., Tamura S. Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J. Biol. Chem. 2001, 276:5753-5759.
127. Prajapati S., Verma U., Yamamoto Y., Kwak Y.T., Gaynor R.B. Protein phosphatase 2Cbeta association with the IkappaB kinase complex is involved in regulating NF-kappaB activity. J. Biol. Chem. 2004, 279:1739-1746.
128. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
129. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
130. Takeuchi T., Kobayashi T., Tamura S., Yokosawa H. Negative regulation of protein phosphatase 2Cbeta by ISG15 conjugation. FEBS Lett. 2006, 580:4521-4526.
131. Zou W., Papov V., Malakhova O., Kim K.I., Dao C., Li J., Zhang D.E. ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem. Biophys. Res. Commun. 2005, 336:61-68.
132. Takeuchi T., Yokosawa H. ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochem. Biophys. Res. Commun. 2005, 336:9-13.
133. VanDemark A.P., Hofmann R.M., Tsui C., Pickart C.M., Wolberger C. Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell 2001, 105:711-720.
134. Moraes T.F., Edwards R.A., McKenna S., Pastushok L., Xiao W., Glover J.N., Ellison M.J. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat. Struct. Biol. 2001, 8:669-673.
135. Osiak A., Utermohlen O., Niendorf S., Horak I., Knobeloch K.P. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell. Biol. 2005, 25:6338-6345.
136. Lenschow D.J., Giannakopoulos N.V., Gunn L.J., Johnston C., O'Guin A.K., Schmidt R.E., Levine B., Virgin H.W.t. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 2005, 79:13974-13983.
137. Harty R.N., Brown M.E., Wang G., Huibregtse J., Hayes F.P. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13871-13876.
138. Ye L., Lin J., Sun Y., Bennouna S., Lo M., Wu Q., Bu Z., Pulendran B., Compans R.W., Yang C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006, 351:260-270.
139. McCarthy S.E., Johnson R.F., Zhang Y.A., Sunyer J.O., Harty R.N. Role for amino acids 212KLR214 of Ebola virus VP40 in assembly and budding. J. Virol. 2007, 81:11452-11460.
140. Licata J.M., Simpson-Holley M., Wright N.T., Han Z., Paragas J., Harty R.N. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J. Virol. 2003, 77:1812-1819.
141. Lu G., Reinert J.T., Pitha-Rowe I., Okumura A., Kellum M., Knobeloch K.P., Hassel B., Pitha P.M. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol. Biol. (Noisy-le-grand) 2006, 52:29-41.
142. Kerscher O., Felberbaum R., Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 2006, 22:159-180.
143. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 2004, 73:355-382.
144. Lowenstein C.J., Padalko E. iNOS (NOS2) at a glance. J. Cell Sci. 2004, 117:2865-2867.
145. Fang F.C. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 1997, 99:2818-2825.
146. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8841-8848.
147. Hess D.T., Matsumoto A., Kim S.O., Marshall H.E., Stamler J.S. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell. Biol. 2005, 6:150-166.
148. Okumura F., Lenschow D.J., Zhang D.E. Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization of ISG15 and contributes to effective ISGylation. J. Biol. Chem. 2008, 283:24484-24488.
149. Cho P.F., Poulin F., Cho-Park Y.A., Cho-Park I.B., Chicoine J.D., Lasko P., Sonenberg N. A new paradigm for translational control: inhibition via 5′-3′ mRNA tethering by Bicoid and the eIF4E cognate 4EHP. Cell 2005, 121:411-423.
150. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
151. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
152. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
153. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3:196-200.
154. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., Endres S., Hartmann G. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
155. Schroder M., Bowie A.G. TLR3 in antiviral immunity: key player or bystander?. Trends Immunol. 2005, 26:462-468.
156. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005, 6:981-988.
157. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
158. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
159. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005, 19:727-740.
160. Kim M.J., Hwang S.Y., Imaizumi T., Yoo J.Y. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 2008, 82:1474-1483.
161. Arimoto K., Takahashi H., Hishiki T., Konishi H., Fujita T., Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7500-7505.
162. Lindner H.A., Fotouhi-Ardakani N., Lytvyn V., Lachance P., Sulea T., Menard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 2005, 79:15199-15208.
163. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
164. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
165. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 2005, 79:2689-2699.
166. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
167. Foy E., Li K., Sumpter R., Loo Y.M., Johnson C.L., Wang C., Fish P.M., Yoneyama M., Fujita T., Lemon S.M., Gale M. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2986-2991.
168. Loo Y.M., Owen D.M., Li K., Erickson A.K., Johnson C.L., Fish P.M., Carney D.S., Wang T., Ishida H., Yoneyama M., Fujita T., Saito T., Lee W.M., Hagedorn C.H., Lau D.T., Weinman S.A., Lemon S.M., Gale M. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6001-6006.
169. Feng Q., Sekula D., Guo Y., Liu X., Black C.C., Galimberti F., Shah S.J., Sempere L.F., Memoli V., Andersen J.B., Hassel B.A., Dragnev K., Dmitrovsky E. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol. Cancer Ther. 2008, 7:3780-3788.
170. Liu M., Li X.L., Hassel B.A. Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15. J. Biol. Chem. 2003, 278:1594-1602.
171. Xiao Y.H., Miller W.H., Warrell R.P., Dmitrovsky E., Zelenetz A.D. Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. Am. J. Pathol. 1993, 143:1301-1311.
172. Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty V.V., Dmitrovsky E., Evans R.M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
173. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., Ohno R., Naoe T. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 1996, 56:2945-2948.
174. Nervi C., Ferrara F.F., Fanelli M., Rippo M.R., Tomassini B., Ferrucci P.F., Ruthardt M., Gelmetti V., Gambacorti-Passerini C., Diverio D., Grignani F., Pelicci P.G., Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 1998, 92:2244-2251.
175. Bektas N., Noetzel E., Veeck J., Press M.F., Kristiansen G., Naami A., Hartmann A., Dimmler A., Beckmann M.W., Knuchel R., Fasching P.A., Dahl E. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008, 10:R58.
176. Desai S.D., Wood L.M., Tsai Y.C., Hsieh T.S., Marks J.R., Scott G.L., Giovanella B.C., Liu L.F. ISG15 as a novel tumor biomarker for drug sensitivity. Mol. Cancer Ther. 2008, 7:1430-1439.
177. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10823-10828.
178. Berger R., Febbo P.G., Majumder P.K., Zhao J.J., Mukherjee S., Signoretti S., Campbell K.T., Sellers W.R., Roberts T.M., Loda M., Golub T.R., Hahn W.C. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004, 64:8867-8875.
179. Kiessling A., Hogrefe C., Erb S., Bobach C., Fuessel S., Wessjohann L., Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 2009, 28:2606-2620.
180. Der S.D., Zhou A., Williams B.R., Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15623-15628.